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ABSTRACT:

Technology and infrastructure costs
can limit access to oral vaccination tools for
wildlife disease control. We describe vaccine bait
mass manufacturing employing off-the-shelf technologies. Our approach has helped advance
scaling-up of plague vaccination campaigns, but
components of this production system could be
translated into other wildlife vaccination applications.

Oral vaccination offers a prospective tool
for controlling a variety of wildlife diseases
(Cross et al. 2007; Artois et al. 2011). The
most notable successes with wildlife vaccination have been the European and North
American campaigns against rabies (Cross et
al. 2007; Sterner et al. 2009; Artois et al.
2011). Mass oral vaccination of wildlife relies
on availability of effective immunogens and
suitable bait delivery technology (Cross et al.
2007; Artois et al. 2011). Unfortunately, the
necessary investments in technology and
infrastructure (Sterner et al. 2009) have
largely limited access to oral vaccination for
large-scale uses other than rabies control.
Versatile and affordable approaches for wildlife vaccination could be beneficial.
Plague—a disease with human and wildlife
health implications—occurs in wild rodent
reservoirs worldwide (World Health Organization 2016). Since its introduction in the
early 1900s, plague has disrupted grassland
and shrub-steppe ecosystems throughout
much of western North America, contributing to the near-extirpation of several native
species, including prairie dogs (Cynomys
spp.; Abbott et al. 2012). Consequently, work
has been underway since the early 2000s to
develop oral vaccination as a plague management tool (Abbott et al. 2012; Johnson et al.
2014; Rocke et al. 2014). Small-scale field
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trials have been undertaken, but landscapescale application via mechanized delivery will
be needed for biologically meaningful plague
control (Johnson et al. 2014; Tripp et al.
2015; USFWS 2016). Here we describe key
elements of a vaccine carrier bait massmanufacturing approach employing off-theshelf technologies. Our approach had immediate application in aiding the development
of mechanical bait distribution for plague
vaccination campaigns in western North
America, but this production system could
be adapted to other wildlife vaccination
applications.
Baits carrying plague vaccine (the genetically-modified raccoonpox virus strain RCNF1/V307; Rocke et al. 2014) consists mainly of
distilled water, an attractant (peanut butter),
and a patented, gelatin-based biopolymer
matrix (Incortrixt, FoodSource Lures Corporation, Birmingham, Alabama, USA) used
previously as a carrier for a recombinant
vaccinia-Lyme disease vaccine (Table 1;
Bhattacharya et al. 2011; FoodSource 2013).
Three critical features of the biopolymer
matrix are: 1) live vaccines can be incorporated into the mix at a temperature low enough
to assure viability; 2) the vaccine bait mixture
remains malleable at this lower temperature;
and 3) the vaccine remains viable through
drying (Bhattacharya et al. 2011; FoodSource
2013). Vaccine-laden baits made with this
matrix can be shaped and sized according to
target species because vaccine is distributed
throughout the bait material.
Bench-top approaches for making vaccine
baits suffice for laboratory studies and smallscale field trials, but cannot support landscape-level endeavors. As a step toward
meeting larger-scale demands, we modified
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TABLE 1. Ingredient amounts in a formulation for
mass-produced baits carrying plague vaccine (RCNF1/V307). We used 8-kg batches as a standard to
accommodate processing through a semiautomated
bait-making machine. See the Supplementary Material
for additional details on vaccine bait making procedures using this system.
Ingredient

Weight (g)

Percentage

Changea

Distilled water
Incortrix powderb
Peanut butterc
Blue dye powder
Vaccine fluid
Total

4,322
2,319
1,159
40
200
8,040

53.8
28.8
14.4
0.5
2.5

1.153
0.823
0.923

a

Multiplier for proportional difference from small-batch formulation provided by the US Geological Survey. Other manipulations explored as overviewed in the Supplementary Material
(Table S1).
b
FoodSource Lures Corporation, Birmingham, Alabama, USA.
c
An organic, pure peanut butter product that does not contain
palm kernel oil or other additives is recommended. See
Supplementary Material Table S1.

bait formulation and manufacturing practices
in order to facilitate adaptive plague vaccination campaigns in Colorado, US and elsewhere. We used a series of exploratory
experiments (Supplementary Material Table
S1) to increase malleability of the vaccine-bait
slurry at room temperature. We ultimately
effected the desired change by increasing
relative water content and allowing ample
time for matrix saturation (Table 1 and
Supplementary Table S1). We also substituted
FD&C Blue #1 food dye for the rhodamine B
biomarker (Fernandez and Rocke 2011) to
decrease bait size, maintain palatability, and
enhance attractiveness to prairie dogs (Cain
and Carlson 1968). This change sacrificed
ability to biomark individuals consuming baits.
Instead, we use observation of blue-stained
feces to confirm vaccine uptake by target
species.
These modifications allowed us to exploit an
off-the-shelf mass production system for bait
manufacture (Fig. 1 and Supplementary
Material). We adapted a ‘‘carp bait’’ production machine (BoilieRoller Machine, Midland
Carp and UAB Topas LT, Tauragė, Lithuania;
Fig. 1A) to make vaccine baits. These

machines produce round, uniform fishing
baits or ‘‘boilies’’ of user-specified diameter.
We elected to produce 14-mm-diameter baits
(mass about 2.1 g wet, each). A video of
vaccine bait manufacturing is given as part of
the Supplementary Material.
We produced vaccine baits under Biosafety Level II conditions (detailed in the
Supplementary Material). Each 8 kg batch
yielded about 3,800 baits, a .10-fold improvement over bench-top production. Initial
steps approximated those of Bhattacharya et
al. (2011): we mixed all ingredients at 65 70
C except the plague vaccine (Yersinia Pestis
Vaccine, Live Raccoon Poxvirus Vector,
Code 11Y2.R0; Colorado Serum Company,
Denver, Colorado, USA), then added the
vaccine after cooling the bait slurry to 35 40
C. We then poured the complete vaccine-bait
mixture—still as a liquid slurry—into an
aluminum extrusion tube. We sealed the
extrusion tubes with plastic wrap to reduce
moisture loss and allowed the formulation to
hydrate and solidify overnight (~12 h) at ~21
C. This essential time period allowed the
matrix to fully hydrate, thereby ensuring
cohesiveness during rolling. After hydration,
the extrusion tube was connected to the
manufacturing machine. Finished baits were
dried for 48 96 h (relative humidity 40%),
then weighed, bagged, and stored frozen
until used. Finished baits weighed 0.9 1 g
dry and remained generally uniform, but
became somewhat less spherical during
drying (Fig. 1B).
Extrusion under pressure 210,000–344,000
pascal (30 50 psi) did not appear to affect
vaccine viability. Dried baits collected from
the beginning and end of runs yielded
comparable live RCN-F1/V307 virus counts
(Supplementary Fig. S1). Virus counts from
dry baits were lower than target doses
(Supplementary Fig. S1) but approximated
the ~10-fold discrepancies between target
and measured RCN counts that we and others
have encountered in bench-top-made vaccine
baits (e.g., Mencher et al. 2004). These
differences could reflect true losses in titer
from the bait-making process or inefficiencies

LETTERS
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FIGURE 1. Plague vaccine baits were mass-produced using off-the-shelf technologies. Clockwise from upper
left: We used a ‘‘boilie’’ machine (A) to manufacture relatively uniform bait balls (~14 mm diameter wet,
~10 12 mm dry) (B) that were readily consumed in the field by prairie dogs (Cynomys spp.; camera trap image)
(C). Blue-stained prairie dog feces (D) deposited across treated field sites confirmed vaccine uptake by the target
species. See the Supplemental Material for a video clip of vaccine bait manufacturing.
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in extraction from the matrix (Mencher et al.
2004).
Manufacturing vaccine baits with boilie
machines was efficient. We produced over
300,000 vaccine baits (~300 kg dry weight) in
an initial 5-wk production run with two
machines. Judging from efficiencies gained
with experience, we anticipate that 100,000
baits/machine-week could be achieved. Labor
savings and formulation modifications cut
estimated per bait production costs by ~50%.
Baits made as described were readily consumed by prairie dogs in the field (Fig. 1C, D)
and already have been field tested in all-terrain
vehicle-mounted delivery platforms and by the
US Fish and Wildlife Service (USFWS) in an
unmanned aerial distribution system (USFWS
2016). Mechanized distribution of baits in the
field is likely to reduce costs further by
replacing ground delivery on foot.
Palatable and homogeneous vaccine baits
produced affordably in large quantities
could be useful in combating wildlife diseases in a variety of species. More accessible
vaccine bait formulation and manufacturing
methods hopefully will facilitate broader
access to oral vaccination for wildlife health
management.
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Division of Parks and Wildlife, Colorado’s
Species Conservation Trust Fund, and Federal Aid in Wildlife Restoration Project
F15AF00515 (W 221 R 1); S.A.S. was supported by USFWS funding. G. Flora, S.
Horton, C. Bunck, C. Puntenney, J. Brooks,
L. Lazenby, K. License, and S. Quigley
worked to mass produce vaccine baits with
boilie machines. We thank Colorado Serum
Company for plague vaccine production, R.
Matchett for suggesting the potential use of
boilie machines in bait making, R. Abbott and
T. Rocke for sharing their recipe for benchtop vaccine bait production, S. Smith for virus
culturing of vaccine baits, S. Wisdom and D.
Miller for consultation and prior work on use
of Incortrix, E. Juodeikis for consultation on
BoilieRoller Machine operation, and J. Eisemann, E. Ruell, and J. O’Hare for logistical
support during bait production.
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